Evidence map›Paper›PMID 35903814›Full record

ArticleDrug delivery2022

Chitosan-modified hollow manganese dioxide nanoparticles loaded with resveratrol for the treatment of spinal cord injury.

Yingqiao Li, Zhiru Zou, Jinyu An, Qian Wu, Le Tong, Xifan Mei, He Tian, Chao Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Advances of MnOFrontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yingqiao LiPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Zhiru ZouPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Jinyu AnPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Qian WuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Le TongPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Xifan MeiDepartment of Orthopedics, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
He TianDepartment of Histology and Embryology, Jinzhou Medical University, Jinzhou, Liaoning, China.
Chao WuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, China.
Jinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal cord injury (SCI) is a serious central nervous system disease, and secondary injury, including oxidative stress, the inflammatory response and accompanying neuronal apoptosis, will aggravate the condition. Due to the existence of the blood-spinal cord barrier (BSCB), the existing drugs for SCI treatment are difficulty to reach the injury site and thus their efficacy is limited. In this study, we designed chitosan-modified hollow manganese dioxide nanoparticles (CM) for the delivery of resveratrol to help it pass through the BSCB. Resveratrol (Res), a poorly soluble drug, was adsorbed into CM with a particle size of approximately 130 nm via the adsorption method, and the drug loading reached 21.39 ± 2.53%.

Indexed as

ChitosanNanoparticlesSpinal Cord InjuriesAnimalsApoptosisCaspase 3Manganese CompoundsOxidative StressOxidesRatsRats, Sprague-DawleyResveratrolCaspase 3ChitosanManganese Compoundsmanganese dioxideOxidesResveratrolapoptosisblood–spinal cord barrierinflammationOxidative stress

Identifiers

PMID35903814
PMCPMC9477490
OpenAlexW4288679642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.